The Biomedical sciences axis  

True pillar of the Poitiers Biopole, the Biomedical Sciences axis brings together a wide array of actors (from the private and public sectors) whose activities perfectly complement each other to form a “drug and clinical trials cluster”.

As of today, the Poitiers Biopole consequently puts forward an overall offer in clinical development that comprises drug candidate identification/screening (BioAlternatives, Cerep), clinical trials (phases I to III) and drug bioanalysis (Aster-Cephac, the Clinical Research Center (CRC) of Poitiers University Hospital, Isoclin, and Parexel Bioanalytical laboratories).
The best in the fight aginst obesity!
Check it!

Fully integrated within the cluster, public research laboratories of the University of Poitiers, the University hospital, the CNRS and the INSERM, have pooled their resources and set up common research programs that focus on drug discovery and organ transplantation.

In addition, the University of Poitiers can pride itself on its two Master’s courses entitled “clinical trials and pharmaceutical marketing”, and “physiology and computer engineering”, which provide a steadily flowing stream of highly qualified students/staff.

Last but not least, in the immediate vicinity of these large-scale structures with their acclaimed know-how, the Poitiers Biopole hosts two start-up companies: BioCydex (advanced drug delivery technology) and @rtMolecule (custom synthesis of organic molecules), as well as two consulting groups specialized in biotechnology: Agenetech, and Value for Growth (V4G).

For details, look in the directory - Biomedical Sciences  
  Legal mentions
English / Anglais Français / French